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production of reactive oxygen species.4-6 Free rad‑
icals, which are generated at the site of inflamma‑
tion and injury,7 can disrupt the balance of nitric 
oxide and damage the endothelium.4
Chronic inflammatory processes cause func‑
tional and structural changes in the vascular en‑
dothelium and affect its activation.2 Endotheli‑
al dysfunction leads to an increased expression 
of cell adhesion molecules, leukocyte diapede‑
sis, vascular smooth ‑muscle tone, excessive per‑
meability of vascular walls, and increased pro‑
coagulant activity.2 Endothelial dysfunction is 
IntroductIon The  vascular endothelium, 
the largest endocrine organ of the human body, 
plays a pivotal role in numerous physiological pro‑
cesses, such as coagulation and fibrinolysis, cell 
proliferation, angiogenesis, regulation of sub‑
stance transport, leukocyte migration across vas‑
cular walls, platelet interaction, and regulation of 
vascular tone.1-3 Endothelial dysfunction is an im‑
balance between vasodilating and vasoconstrict‑
ing substances produced by (or affecting) endo‑
thelial cells.4,5 It is characterized by a decreased 
bioavailability of nitric oxide due to an increased 
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AbstrAct
IntroductIon Endothelial dysfunction leads to an increased expression of cell adhesion molecules, 
leukocyte diapedesis, vascular smooth ‑muscle tone, excessive permeability of vascular walls, and 
increased procoagulant activity.
objEctIvEs We investigated whether serum levels of several endothelial and platelet activation markers 
correlated with disease activity in patients with inflammatory bowel disease (IBD).
PAtIEnts And mEthods This study included 56 patients with ulcerative colitis, 66 with Crohn disease, 
and 40 healthy controls. We measured the complete blood count and levels of fibrinogen, C ‑reactive 
protein, albumin, interleukin 6, tumor necrosis factor α, E ‑selectin, P ‑selectin, monocyte chemoattractant 
protein 1 (MCP ‑1), soluble CD40 ligand (sCD40L), and microparticles.
rEsuLts There were no significant differences in the median levels of E ‑selectin, P ‑selectin, MCP ‑1, 
sCD40L, and microparticles between patients with active IBD, those with inactive IBD, and healthy 
controls. The clinical disease activity assessed with the Mayo scale in the ulcerative ‑colitis group was 
weakly, positively correlated with sCD40L (R = 0.32, P = 0.02), P ‑selectin (R = 0.32, P = 0.02), and 
inflammatory marker levels. The clinical disease activity index in the Crohn disease group was positively 
correlated with the markers of inflammation yet not with the markers of endothelial activity.
concLusIons E ‑selectin, P ‑selectin, sCD40L, MCP ‑1, and microparticle levels do not significantly differ 
between patients with the varying activity of IBD. However, due to the observed correlations, further 
studies of a larger patient group should be conducted to confirm our observations.
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at Jagiellonian University in Kraków, Poland 
(KBET/54/B/2012).
The study prospectively enrolled 56 patients 
with ulcerative colitis (median age [interquartile 
range (IQR)], 37 [26–51.25] years; 28 men) and 
66 patients with Crohn disease (median [IQR] 
age, 31 [26–37] years; 33 men). Inflammatory 
bowel disease was diagnosed using clinical, radio‑
logical, endoscopic, and histopathological crite‑
ria.11 Based on 2 scores, the study patients were 
divided into subgroups with inactive Crohn dis‑
ease (Crohn disease activity index [CDAI] <150) 
and active Crohn disease (CDAI ≥150); and inac‑
tive ulcerative colitis (Mayo scale score <4) and 
active ulcerative colitis (Mayo scale score ≥4).12,13 
The control group included 40 healthy volunteers 
(median [IQR] age, 32 [25–45] years).
The exclusion criteria were as follows: any 
known acute or chronic infection, pregnancy or 
lactation, autoimmune diseases, rheumatoid ar‑
thritis, hypertension, coronary artery disease, 
chronic heart failure, diabetes, dyslipidemia, 
chronic kidney disease, severe respiratory failure, 
peripheral vascular disease, stroke, venous throm‑
bosis, hematologic disorders, or malignancies.
methods Patient demographics, clinical char‑
acteristics, results of gastrointestinal tract ex‑
amination, IBD history, and treatments were 
recorded and the body mass index (BMI) was 
calculated. Blood samples were collected after 
an overnight fast and on the same day. A com‑
plete blood count, a lipid profile, and C ‑reactive 
protein (CRP), albumin, alanine aminotransfer‑
ase, creatinine, glucose, and fibrinogen levels were 
measured in the hospital laboratory using stan‑
dard procedures.
Serum was obtained from another blood sam‑
ple, which was later used to determine interleu‑
kin 6 (IL ‑6), tumor necrosis factor α (TNF ‑α), 
E ‑selectin, P ‑selectin, MCP ‑1, sCD40L, and mi‑
croparticle levels.
An  enzyme ‑linked immunosorbent assay 
(ELISA) was used to measure IL ‑6 (IL ‑6 HS, R&D 
Systems, Minneapolis, Minnesota, United States) 
and TNF ‑α levels (TNF HS, R&D Systems).
P ‑selectin, E ‑selectin, sCD40L, and MCP ‑1 se‑
rum levels were determined using an ELISA ac‑
cording to the manufacturer’s instructions (Hu‑
man CCL2 / MCP ‑1 Quantikine ELISA kit, Hu‑
man CD40 ligand / TNFSF5 Quantikine ELISA 
kit, Human P ‑selectin / CD62P Quantikine ELISA 
kit, Human sE ‑selectin / CD62E Quantikine ELI‑
SA kit; R&D Systems). Optical density was mea‑
sured on a plate reader (450 ‑nm wavelength), 
and data were collected using the Gen 5 soft‑
ware (BioTek, Winooski, Vermont, United States). 
A 4 ‑parameter curve fit was used to generate 
the standard curve.
Microparticle procoagulant activity in human 
serum was determined using an ELISA according 
to the manufacturer’s instructions (Zymuphen 
MP ‑Activity, Hyphen BioMed, Neuville ‑sur ‑Oise, 
France). Optical density was measured on a plate 
involved in various diseases, including periph‑
eral vascular disease, stroke, venous thrombo‑
sis, diabetes, insulin resistance, hypercholester‑
olemia, cardiac disease, tumor growth and me‑
tastasis, chronic kidney failure, rheumatoid ar‑
thritis, viral infections, and inflammatory bow‑
el disease (IBD).2,4,7-10
The multifactorial etiology of IBD requires fur‑
ther elucidation. Genetically predisposed patients 
with ulcerative colitis and Crohn disease show 
changes in gut microbiota, disruption of epithe‑
lial barrier function, and chronic immune activa‑
tion.7,10 In addition, oxidative stress causes gas‑
trointestinal tract injury.1,6,8
Physical and biochemical methods can be used 
to assess endothelial cell activity, such as the re‑
lease of substances from a normal or damaged en‑
dothelium.2 Cellular or chemical biomarkers com‑
prise factors released by endothelial cells, such 
as cell adhesion molecules, vascular endothelial 
growth factor, von Willebrand factor, tissue plas‑
minogen activator, thrombomodulin, asymmet‑
ric dimethylarginine, disintegrin and metallopro‑
teinase with thrombospondin motif 13, and an‑
giopoietins5,7-10 or recently discovered micropar‑
ticles, vesicles released by endothelial cells, plate‑
lets, erythrocytes, monocytes, and lymphocytes 
(from their cell membranes).10
This study compared the serum levels of en‑
dothelial dysfunction biomarkers (E ‑selectin and 
P ‑selectin), monocyte chemoattractant protein 1 
(MCP ‑1), and soluble CD40 ligand (sCD40L), as 
well as microparticle activity, between patients 
with IBD and healthy controls. We investigated 
the potential association of these markers with 
clinical disease activity in patients with IBD.
PAtIEnts And mEthods study population 
Study participants were recruited from the De‑
partment of Gastroenterology and Hepatology 
of the University Hospital in Kraków, Poland. 
All of them signed a written informed consent 
form, and the study was conducted in accor‑
dance with the Declaration of Helsinki. The pro‑
tocol was approved by the Bioethics Committee 
whAt’s nEw?
The intestinal vascular microcirculation plays a relevant role in the initiation 
and maintenance of the inflammatory process. It regulates the recruitment of 
leukocytes from the vascular circulation into inflamed tissues and expresses cell 
adhesion molecules and chemokines that enhance interactions with leukocytes. 
Endothelial dysfunction is observed in various diseases, including inflammatory 
bowel disease (IBD). To assess endothelial cell activity, biochemical methods 
such as the release of substances from a normal or damaged endothelium 
can be used. We investigated serum levels of selected endothelial activation 
markers in patients with a varying activity of IBD. Our study did not show any 
significant differences in levels of E ‑selectin, P ‑selectin, monocyte chemoat‑
tractant protein 1, soluble CD40 ligand, and microparticles in patients with 
active IBD, those with inactive IBD, and healthy controls. However, further 
studies including large samples are needed to confirm these observations.
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complications. None of them had stoma. Two pa‑
tients underwent right hemicolectomy.
Among the study patients with ulcerative coli‑
tis, disease remission was observed in 19 (34%) in‑
dividuals, mild disease exacerbation in 17 (26%), 
moderate exacerbation in 18 (32%), and severe ex‑
acerbation in 2 (3.6%). Among those with Crohn 
disease, 33 (50%) were in remission, 12 (18%) had 
mild disease exacerbation, 21 (32%) moderate ex‑
acerbation, and none of the patients experienced 
severe exacerbation.
Laboratory test results Patients with active IBD 
had significantly higher levels of inflammatory 
markers (white blood cells [WBCs], CRP, fibrino‑
gen, and IL ‑6) compared with those with inactive 
disease and controls (tAbLEs 2 and 3).
The active and inactive subgroups of patients 
with ulcerative colitis and Crohn disease showed 
no differences in microparticle activity and levels 
of selectins, sCD40L, or MCP ‑1 (tAbLEs 2 and 3). In 
the ulcerative colitis group, no differences were 
found in the levels of the analyzed markers de‑
pending on various stages of the disease (tAbLE 4). 
Patients with severe flare were excluded from this 
analysis because of the limited number of subjects.
Patients with inactive Crohn disease, those 
at various stages of active Crohn disease, and con‑
trols showed no difference in microparticle activ‑
ity or levels of selectins or sCD40L (tAbLE 5). Pa‑
tients with moderate Crohn disease had a high‑
er median (IQR) level of MCP ‑1 than those with 
mild disease (144.01 [87.59–221.84] vs 94.81 
[85.23–122.2] pg/ml; P = 0.04). The study did 
not reveal any differences in patients with Crohn 
disease with or without a history of surgery: mi‑
croparticles (median [IQR], 23.68 [11.72–34.78] 
vs 17.23 [11.79–27.19] nM; P = 0.33), sCD40L 
(206.61 [147.3–719.69] vs 318.26 [178.84–
776.27] pg/ml; P = 0.41), MCP ‑1 (149.96 [91.79–
210.9] vs 125.98 [86.5–188.06] pg/ml; P = 0.25), 
E ‑selectin (27.25 [20.25–35.19] vs 26.8 [17.53–
36.46] ng/ml; P = 0.69), P ‑selectin (40 [34.08–
53.06] vs 39.08 [31.76–47.08] ng/ml; P = 0.33).
reader (450 ‑nm wavelength), and data were col‑
lected using the Gen 5 software (BioTek). Lin‑
ear curve fitting was used to generate the stan‑
dard curve.
statistical analysis Statistical analyses were per‑
formed using the Statistica software, version 12.0 
(StatSoft, Inc., Tulsa, Oklahoma, United States). 
Data were expressed as percentage (categori‑
cal variables), mean (SD) (normally distributed 
variables), and median and interquartile range 
(nonnormally distributed continuous variables). 
The Shapiro–Wilk test was used to assess the nor‑
mality of data distribution. The analysis of vari‑
ance and the Kruskal–Wallis test were used to 
compare continuous variables. The Tukey test or 
the Dunn–Bonferroni approach were applied for 
pairwise comparison for post hoc testing after 
the analysis of variance and the Kruskal–Wallis 
test, respectively. Categorical variables were an‑
alyzed using the χ2 test. The associations among 
clinical characteristics, IBD activity, and biochem‑
ical parameters were evaluated by calculating 
the Spearman rank correlation coefficient. A P val‑
ue less than 0.05 was considered significant.
rEsuLts Patient characteristics Detailed patient 
characteristics are presented in tAbLE 1. No signifi‑
cant differences in sex, age, BMI, or smoking hab‑
its were detected between the study groups. All 
patients with ulcerative colitis received mesala‑
mine (2–4 g/d), 12 patients (21%) were on main‑
tenance therapy with thiopurines, 17 (30%) re‑
ceived glucocorticoids, and 2 (3.6%) received bio‑
logical treatment with infliximab. Among patients 
with Crohn disease, those with disease location 
at L2 and L3 received mesalamine (2–4 g/d), 30 
individuals (45%) were on maintenance immu‑
nosuppressive therapy, 23 (35%) received gluco‑
corticoids, and 4 (6%) received biological treat‑
ment with infliximab or adalimumab. None of 
the study patients had undergone surgery for ul‑
cerative colitis. However, 31 patients (47%) with 
Crohn disease had at least 1 surgery due to disease 
tAbLE 1 Patient characteristics







Male sex, n (%) 28 (50) 33 (50) 20 (50) 0.99
Age, y, median (IQR) 37 (26–51.2) 31 (26–37) 32 (25–45) 0.06
BMI, kg/m2, median (IQR) 22.7 (19.6–25.1) 21.5 (18.7–24.4) 23.4 (20.8–26) 0.08
Smoking status, n (%) 8 (14.3) 17 (25.8) 10 (25) 0.23
Disease duration, y, median (IQR) 6 (2–11) 4 (1–9) – 0.14
Disease location, n (%) E1 (proctitis) 5 (8.9) – – –
E2 (left ‑sided) 28 (50) – – –
E3 (extensive) 23 (41.1) – – –
L1 (ileum) – 13 (19.7) – –
L2 (colon) – 10 (15.2) – –
L3 (ileocolon) – 43 (65.1) – –
Abbreviations: BMI, body mass index; IQR, interquartile range
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tAbLE 2 Endothelial activation and inflammatory markers in patients with active or inactive ulcerative colitis and 
healthy controls
Parameter Inactive ulcerative colitis 
(n = 19)





Microparticles, nM 14.78 (6.29–35.6) 24.4 (14.49–44.47) 30.04 (17.32–42.88) 0.07
sCD40L, pg/ml 196.83 (130.25–414.07) 353.8 (155.45–543.93) 295.92 (121.4–694.98) 0.05
MCP ‑1, pg/ml 121.9 (87.34–168.35) 129.44 (105.02–173.79) 149.06 (106.2–229.24) 0.19
E ‑selectin, ng/ml 21.34 (18.51–32.06) 25.37 (19.19–29.87) 25.87 (17.52–32.34) 0.83
P ‑selectin, ng/ml 36.36 (28.56–49.38) 40.26 (33.66–53.22) 43.29 (37.35–54.7) 0.08
Albumin, g/l 45 (44–47) 41a,b (35–44) 47 (43–48) <0.001
CRP, mg/l 0.99 (0.71–1.72) 8.63a,b (4.02–28) 0.94 (0.47–1.39) <0.001
Fibrinogen, g/l 2.56 (2.25–3.43) 4.32a,b (3.55–5.9) 2.8 (2.45–3.1) <0.001
IL ‑6, pg/ml 1.37 (0.88–2.46) 3.36a,b (1.66–6.65) 1.43 (0.94–2.13) 0.001
PLT, × 103/μl 235 (205–295) 270b (231–359) 224 (185–252) 0.01
TNF ‑α, pg/ml 1.23 (1.02–3.37) 1.89a (1.38–3.05) 1.66 (1.11–3.23) 0.39
WBC, × 103/μl 5.82 (4.63–6.8) 7.46a,b (6.47–9.92) 5.75 (4.65–7.6) <0.001
Data are presented as median (interquartile range).
a A significant difference was found between the active ulcerative ‑colitis and inactive ulcerative ‑colitis groups.
b A significant difference was found between the active ulcerative ‑colitis and control groups.
Abbreviations: CRP, C ‑reactive protein; IL ‑6, interleukin 6; MCP ‑1, monocyte chemoattractant protein 1; PLT, platelets; 
sCD40L, soluble CD40 ligand; TNF ‑α, tumor necrosis factor α; WBC, white blood cell
tAbLE 3 Endothelial activation and inflammatory markers in patients with active or inactive Crohn disease and 
healthy controls
Parameter Inactive Crohn disease 
(n = 33)





Microparticles, nM 18.63 (12.94–31.06) 19.41 (11.55–34.71) 30.04 (17.32–42.88) 0.09
sCD40L, pg/ml 225.58 (157.58–501.36) 281.49 (179.77–719.69) 295.92 (121.4–694.98) 0.74
MCP ‑1, pg/ml 145.43 (100.63–189.27) 129.46 (87.34–210.91) 149.06 (106.2–229.24) 0.19
E ‑selectin, ng/ml 21.7 (18.45–29.48) 27.92 (23.29–39.17) 25.87 (17.52–32.34) 0.09
P ‑selectin, ng/ml 39.89 (31.94–46.55) 39.78 (33.36–47.08) 43.29 (37.35–54.7) 0.3
Albumin, g/l 45 (41–47) 37a,b (35–42) 47 (43–48) <0.001
CRP, mg/l 1.31 (0.9–3.48) 23.2a,b (10.8–44.6) 0.94 (0.47–1.39) <0.001
Fibrinogen, g/l 3.42 (2.68–3.97) 5.38a,b (4.76–6.04) 2.8 (2.45–3.1) <0.001
IL ‑6, pg/ml 1.37 (0.92–3.16) 4.07a,b (2.11–6.51) 1.43 (0.94–2.13) <0.001
PLT, × 103/μl 279 (223–311) 332a,b (280–420) 224 (185–252) <0.001
TNF ‑α, pg/ml 1.48 (0.98–2.2) 1.64 (1.27–2.17) 1.66 (1.11–3.23) 0.63
WBC, × 103/μl 5.95 (5.47–7.08) 7.36b (6.21–9.93) 5.75 (4.65–7.6) 0.006
Data are presented as median (interquartile range).
a A significant difference was found between the active Crohn ‑disease and inactive Crohn ‑disease groups.
b A significant difference was found between the active Crohn ‑disease and control groups.
Abbreviations: see tAbLE 2
tAbLE 4 Markers of endothelial activation at various activity stages of ulcerative colitis
Parameter Mayo score, 0–2 
(n = 19)
Mayo score, 3–5 
(n = 11)
Mayo score, 6–10 
(n = 24)
P value
Microparticles, nM 14.78 (6.29–35.66) 26.58 (14.48–40.65) 26.77 (14.5–55.86) 0.09
sCD40L, pg/ml 196.83 (130.25–414.07) 135.65 (114.04–386.43) 416.6 (200.15–625.15) 0.07
MCP ‑1, pg/ml 121.91 (87.34–168.35) 110.86 (101.18–151.13) 133.18 (100.62–183.04) 0.69
E ‑selectin, ng/ml 21.34 (18.51–32.06) 20.05 (18.65–26.05) 25.76 (21.26–32.64) 0.22
P‑selectin, ng/ml 36.36 (28.56–49.38) 33.66 (32–40.28) 43.32 (37.6–55.7) 0.11
Data are presented as median (interquartile range).
Abbreviations: see tAbLE 2
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hemoglobin (R = –0.32, P = 0.01) and albumin lev‑
els (R = –0.54, P <0.001). In the ulcerative colitis 
group, the only markers of endothelial dysfunc‑
tion that showed a correlation were E ‑selectin and 
P ‑selectin levels (R = 0.56, P <0.001).
In the Crohn disease group, although CDAI 
did not correlate with the analyzed markers, we 
found a positive correlation with CRP (R = 0.71, 
P <0.001), fibrinogen (R = 0.61, P <0.001), WBC 
(R = 0.29, P = 0.02), platelet (R = 0.51, P <0.001), 
and IL ‑6 (R = 0.35, P = 0.004) levels, yet a negative 
correlation with hemoglobin (R = –0.71, P <0.001) 
and albumin levels (R = –0.66, P <0.001). The mi‑
croparticle activity positively correlated with 
sCD40L (R = 0.27, P = 0.025) and MCP ‑1 (R = 0.24, 
P = 0.046) levels, and negatively, with E ‑selec‑
tin levels (R = –0.25, P = 0.04). P ‑selectin levels 
positively correlated with MCP ‑1 levels (R = 0.3, 
P = 0.01).
In the control group, P ‑selectin levels positively 
correlated with microparticle (R = 0.6, P <0.001), 
In patients with ulcerative colitis and those 
with Crohn disease, no differences were also 
found in the levels of endothelial dysfunction 
parameters depending on the type of therapy 
used (tAbLE 6). However, patients with active IBD 
who were on maintenance immunosuppressive 
therapy had a lower median microparticle activ‑
ity compared with those taking mesalamine only 
(16.13 [9.04–26.58] vs 26.94 [16.81–49.33] nM; 
P = 0.01). Patients receiving biological treat‑
ment were excluded from this analysis because 
of the limited number of subjects.
correlations between the analyzed parameters In 
the ulcerative colitis group, disease activity (as‑
sessed using the Mayo scale) correlated positive‑
ly with sCD40L (R = 0.32, P = 0.02), P ‑selectin 
(R = 0.32, P = 0.02), WBC (R = 0.52, P <0.001), 
platelet (R = 0.38, P <0.001), fibrinogen (R = 0.63, 
P <0.001), TNF ‑α (R = 0.27, P = 0.047), and IL ‑6 
(R = 0.47, P <0.001) levels, and negatively with 
tAbLE 5 Markers of endothelial activation at various activity stages of Crohn disease
Parameter CDAI <150 (n = 33) CDAI, 150–220 (n = 12) CDAI, 221–450 (n = 21) P value
Microparticles, nM, 
median (IQR)
18.63 (12–36.94) 18.6 (13.04–27.48) 19.41 (11.55–47.92) 0.97
sCD40L, pg/ml, 
median (IQR)
225.58 (157.48–501.36) 214.32 (74.22–666.13) 452.78 (179.77–897.06) 0.69
MCP ‑1, pg/ml, median 
(IQR)
145.43 (100.63–189.27) 94.81 (85.23–122.2) 144.01 (87.59–221.84) 0.04
E ‑selectin, ng/ml, 
mean (SD)
24.47 (8.72) 32.12 (15.64) 31.87 (14.98) 0.06
P ‑selectin, ng/ml, 
mean (SD)
41.95 (14.37) 38.27 (13.12) 49.17 (21.17) 0.15
Abbreviations: CDAI, Crohn disease activity index; others, see tAbLE 2
tAbLE 6 Markers of endothelial activation depending on the treatment used




Patients, n 32 12 6 4 –
MPs, nM 28.4 (14.58–45.26) 14.93 (9.82–40.42) 9.61 (8.49–39.92) 27.15 (15.33–14.77) 0.44
sCD40L, pg/ml 241.83 (129.35–470.3) 543.93 (122.9–1005.39) 226.53 (201.86–414.07) 306.91 (181.53–412.87) 0.66
MCP ‑1, pg/ml 114.49 (91.74–153.07) 135.17 (82.77–237.7) 144.59 (122.46–178.02) 140.04 (98.78–247.87) 0.53
E ‑selectin, ng/ml 25.55 (19.31–29.74) 21.58 (19.18–24.45) 32.95 (19.28–34.38) 23.61 (16.84–30.99) 0.33
P‑selectin, ng/ml 40.28 (32–53.4) 34.86 (29.02–44.69) 42.32 (38.4–45.26) 40.23 (27.98–61.92) 0.54
Crohn disease
Patients, n 22 14 17 9 –
Microparticles, nM 23.53 (12.1–44.59) 16.3 (9.72–26.37) 18.62 (16.25–34.78) 15.54 (11.79–23.08) 0.65
sCD40L, pg/ml 437.63 (147.3–964.72) 200.76 (157.58–261.65) 384.64 (206.61–948.86) 210.34 (157.58–452.78) 0.24
MCP ‑1, pg/ml 160.6 (91.79–210.67) 124.95 (87.34–146.86) 129.46 (95.73–151.64) 134.63 (90.22–188.06) 0.75
E ‑selectin, ng/ml 21.1 (19.36–28.96) 27.85 (14.32–37.35) 30.04 (24.59–36.46) 28.53 (23.38–36.8) 0.17
P ‑selectin, ng/ml 39.89 (38.06–58.6) 38.34 (32.46–42.74) 39.78 (33.36–66.26) 35.66 (28.56–40) 0.46
Data are presented as median (interquartile range) unless otherwise indicated.
All patients with ulcerative colitis were on maintenance therapy with mesalamine. Patients with Crohn disease location L2 and L3 received 
mesalamine.
Abbreviations: see tAbLE 2
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Although several studies have assessed vari‑
ous markers of endothelial activity in patients 
with IBD, the results are inconclusive. Conflict‑
ing with some studies, our results showed no dif‑
ferences in serum microparticle activity or serum 
levels of MCP ‑1, sCD40L, E ‑selectin, and P ‑selec‑
tin between patients with IBD and controls. P ‑se‑
lectin was the only marker that showed a reduced 
level in patients with inactive ulcerative colitis.
P ‑selectin, a member of the cell adhesion mol‑
ecule family, is produced in cytoplasmic secretory 
α‑granules of platelets and endothelial cells.18 It 
is one of the most active factors secreted by en‑
dothelial cells, which mediates the activation of 
leukocytes and adhesion of platelets at the site of 
vascular injury.4 A high concentration of soluble 
P ‑selectin is a marker of platelet activation, in‑
flammation, and endothelial dysfunction.10,19 Pa‑
tients with IBD show an increased soluble P ‑selec‑
tin fraction and expression of P ‑selectin in the in‑
flamed mucosa.18-20 However, noninflamed tis‑
sues of patients with IBD show decreased levels 
of P ‑selectin expression, comparable with those 
seen in healthy controls.20 Secretion of P ‑selectin 
induces leukocyte rolling, followed by leukocyte 
adhesion and migration to the inflamed mucosa.4 
In our study, the median level of P ‑selectin was 
decreased in patients with inactive ulcerative coli‑
tis compared with those with the active disease 
and controls, correlating with numerous inflam‑
matory markers. In contrast, the Crohn disease 
group showed no differences between the active 
and inactive subgroups and no correlations were 
sCD40L (R = 0.35, P = 0.02), MCP ‑1 (R = 0.5, 
P = 0.001), and E ‑selectin (R = 0.46, P = 0.003) 
levels, and MCP ‑1 levels positively correlated 
with microparticle (R = 0.4, P = 0.01), sCD40L 
(R = 0.62, P <0.001), and E ‑selectin (R = 0.32, 
P = 0.04) levels.
Correlations between the markers of endo‑
thelial dysfunction and inflammation in the ul‑
cerative colitis and Crohn disease groups are pre‑
sented in tAbLEs 7 and 8, respectively.
dIscussIon This study revealed that patients 
with inactive and active IBD and controls did not 
differ significantly regarding P ‑selectin, E ‑selectin, 
sCD40L, MCP ‑1, or microparticle levels. More‑
over, in contrast to healthy controls, the select‑
ed markers in patients with IBD showed no (or 
only weak or very weak) correlations with each 
other, except for P ‑selectin and E ‑selectin levels 
in patients with ulcerative colitis.
Patients with ulcerative colitis and Crohn dis‑
ease have disrupted immune systems14 and in‑
creased permeability of the epithelial barrier.15 
Thus, antigens are exposed to granulocytes, lym‑
phocytes, and dendritic cells through the dam‑
aged submucosa.14 Tissue ‑damaging proteases, 
proinflammatory cytokines, and vasoactive pep‑
tides are released from neutrophils and mast cells, 
causing mucositis.16 Activated T cells demonstrate 
delayed apoptosis and persist in the mucosa, con‑
tributing to chronic inflammation.14,16 Further‑
more, activated platelets can modulate the activ‑
ity of endothelial cells.17
tAbLE 7 Correlations between endothelial activation and inflammatory markers in patients with ulcerative colitis
Parameter Microparticles sCD40L MCP ‑1 E ‑selectin P ‑selectin
R value P value R value P value R value P value R value P value R value P value
CRP 0.13 0.33 0.14 0.31 0.07 0.64 0.37 0.006 0.36 0.008
WBC 0.36 0.007 0.2 0.15 0.03 0.82 0.29 0.03 0.25 0.07
PLT 0.31 0.02 0.15 0.27 0.11 0.42 0.25 0.07 0.31 0.02
Albumin –0.1 0.48 –0.39 0.004 –0.2 0.14 –0.24 0.08 –0.28 0.04
Fibrinogen 0.31 0.02 0.17 0.2 0.18 0.19 0.26 0.06 0.34 0.01
TNF ‑α 0.23 0.08 0.32 0.02 0.35 0.01 0.48 <0.001 0.2 0.14
IL ‑6 0.15 0.29 0.31 0.02 0.3 0.02 0.42 0.002 0.28 0.04
Abbreviations: see tAbLE 2
tAbLE 8 Correlations between endothelial activation and inflammatory markers in patients with Crohn disease
Parameter Microparticles sCD40L MCP ‑1 E ‑selectin P ‑selectin
R value P value R value P value R value P value R value P value R value P value
CRP 0.04 0.75 –0.009 0.94 –0.07 0.59 0.28 0.02 0.03 0.79
WBC –0.03 0.81 0.05 0.72 –0.05 0.67 0.35 0.005 0.33 0.008
PLT 0.15 0.24 0.2 0.12 0.08 0.54 0.06 0.63 0.19 0.13
Albumin –0.22 0.08 –0.25 0.04 –0.01 0.94 –0.15 0.24 0.007 0.007
Fibrinogen 0.003 0.98 –0.08 0.52 –0.05 0.67 0.25 0.05 0.08 0.55
TNF ‑α –0.03 0.85 0.24 0.06 –0.08 0.52 0.47 <0.001 –0.03 0.8
IL ‑6 0.31 0.01 0.13 0.3 0.14 0.28 0.23 0.052 0.06 0.64
Abbreviations: see tAbLE 2
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endothelial cells, smooth muscle cells, and can‑
cer cells.31,32 Microparticles in body fluids may re‑
flect stem cell damage. They contain the antigens 
of their cell of origin and can transfer these sur‑
face molecules to other cell types.33 Microparti‑
cles play a role in hemostatic and inflammatory 
processes, vascular remodeling and angiogene‑
sis, cell survival, and apoptosis.30 The cellular ori‑
gin of circulating microparticles is dependent on 
the type of disease, its status, and medical treat‑
ment.32 For example, the level of microparticles 
can be decreased by numerous medications, in‑
cluding statins, fibrates, β ‑blockers, and inflix‑
imab.30,34 Under physiological conditions, lev‑
els of microparticles and circulating endothelial 
cells are low; however, they increase with age.34 
Production of microparticles can be enhanced by 
inflammatory conditions. Voudoukis et al31 re‑
ported lower levels of microparticles in patients 
with inactive IBD compared with controls, yet in‑
creased levels of microparticles in patients with 
active IBD. Similarly, several studies showed ele‑
vated levels of microparticles in patients with ac‑
tive Crohn disease35 or IBD.36 In our study, only 
patients with ulcerative colitis showed a tenden‑
cy towards increased microparticle levels with in‑
creasing disease severity. Of note, the use of im‑
munosuppressive therapy was associated with 
lower levels of serum microparticles in patients 
with the active disease.
Mesri et al37 showed that microparticles in‑
duced IL ‑6 and MCP ‑1 release in healthy volun‑
teers and tissue factor expression by endothelial 
cells in vitro. Monocyte chemoattractant protein 1 
is produced by dendritic cells, macrophages, fibro‑
blasts, and epithelial and endothelial cells after 
exposure to TNF ‑α or IL ‑1.38 It acts as a chemoat‑
tractant for inflammatory cells such as mono‑
cytes, lymphocytes, and natural killer cells.39 In‑
terleukin 1β released from activated platelets in‑
duces endothelial MCP ‑1, leading to enhanced 
adhesion of neutrophils to the endothelium.17 
Increased levels of MCP ‑1 have been found in 
the mucosa of patients with IBD and in the ex‑
perimental models of colitis.40 Khan et al38 re‑
ported that mice lacking the MCP ‑1 gene had less 
severe macroscopic and histologic changes when 
subjected to dinitrobenzenesulfonic acid–induced 
colitis. Furthermore, interferon γ production was 
reduced. In contrast, the MCP ‑1+/+ mice showed 
an increased number of colonic enterochromaf‑
fin cells, which was not evident in the MCP ‑1–/– 
mice.38 Monocyte chemoattractant protein 1 dis‑
turbs differentiation of monocytes into intesti‑
nal macrophages, which may result in the persis‑
tence of a reactive macrophage population and 
chronic inflammation.39 Motomura et al40 report‑
ed that MCP ‑1 enhances the production of trans‑
forming growth factor β, matrix metalloprotein‑
ase 3, and the tissue inhibitor of metalloprotein‑
ase 1, which contributes to intestinal fibrosis. Al‑
though increased MCP ‑1 serum levels have been 
found in patients with IBD, this does not always 
correlate with its intestinal expression.41 In our 
found, except for WBCs. However, Magro et al21 
reported a lower P ‑selectin level in patients with 
active and inactive IBD compared with controls. 
The authors observed a membrane ‑bound expres‑
sion of P ‑selectin molecules on the surface of en‑
dothelial cells, so they suggested that low levels 
of serum selectins in patients with IBD may be 
explained by a decreased cleavage from the sur‑
face of endothelial cells.21 In addition, this find‑
ing indicated persistent leukocyte activation dur‑
ing remission.21
Most endothelial cells (aside from bone mar‑
row endothelial cells) produce and express E ‑se‑
lectin (an endothelial leukocyte adhesion mole‑
cule) only after activation of the inflammatory 
process in response to IL ‑1β and TNF ‑α.22 E ‑se‑
lectin is involved in inducing leukocyte rolling on 
the endothelial surface.21 In 1997, Cellier et al23 
showed a positive correlation between E ‑selec‑
tin expression in intestinal biopsies and the clin‑
ical and endoscopic severity of IBD. In contrast, 
Gu et al24 found no difference in E ‑selectin or 
P ‑selectin expression among 40 patients with 
IBD with and without relapse. No E ‑selectin ex‑
pression was observed in the intestinal tissues of 
patients with IBD remission.25
In our study, we found no difference in the se‑
rum level of E ‑selectin in patients with active ver‑
sus inactive ulcerative colitis. However, there was 
a trend towards a lower E ‑selectin level in the in‑
active Crohn disease group compared with the ac‑
tive one (P = 0.052). The E ‑selectin concentration 
positively correlated with numerous inflammato‑
ry markers such as CRP, WBC, TNF ‑α, and IL ‑6 in 
patients with ulcerative colitis, and with fibrino‑
gen in patients with Crohn disease. However, no 
correlation with clinical disease activity assessed 
with CDAI and the Mayo scale was found. These 
results are in accordance with observations from 
several studies conducted in smaller groups of pa‑
tients.26,27 In a cohort of 40 patients with IBD, 
Trzeciak ‑Jędrzejczyk et al26 found no differences 
in serum E ‑selectin levels among ulcerative colitis, 
Crohn disease, and control groups. Several studies 
showed an increased serum E ‑selectin level only 
in patients with active Crohn disease compared 
with those with the quiescent disease.28,29 Inter‑
estingly, Magro et al21 reported a lower E ‑selec‑
tin concentration in patients (145 subjects) with 
inactive and biologically active (high CRP levels) 
Crohn disease compared with controls and clin‑
ically active groups. In their study, patients with 
ulcerative colitis (73 subjects) showed no differ‑
ence in E ‑selectin concentrations between bi‑
ologically active, clinically active, inactive, and 
healthy control groups.21 The differences between 
studies are likely due to various characteristics of 
the study groups.
Similarly, microparticle formation is enhanced 
during inflammation and under oxidative stress.17 
Fragments of microparticles released from stimu‑
lated or apoptotic cells after plasma membrane re‑
modeling30 are mostly derived from platelets (70% 
to 90%) but also from leukocytes, erythrocytes, 
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the study results, several confounding factors, 
such as concomitant medication, smoking status, 
BMI, and the level of physical activity, may have 
influenced endothelial dysfunction.7 Moreover, 
iron deficiency, a frequently observed condition 
in patients with IBD, may contribute to platelet 
overproduction.50
Due to complexity of endothelial function, se‑
rum biomarkers may represent different aspects 
of its activity.
Our study revealed that the serum levels of 
E ‑selectin, P ‑selectin, MCP ‑1, and sCD40L and 
the activity of microparticles should not be re‑
garded as clinical markers of IBD activity. Howev‑
er, other studies have suggested that these param‑
eters could be potential indicators of several IBD‑
‑related conditions, such as an increased throm‑
botic risk (microparticles),17,50 fibrosis (MCP ‑1),39 
or response to medication (sCD40L).49
Admittedly, our study had some limitations. 
First, it included a relatively small number of pa‑
tients. Second, we did not perform an endoscopic 
assessment of Crohn disease activity in patients 
and based the analysis only on CDAI, which poor‑
ly correlates with disease activity evaluated in 
endoscopic and histological examinations and 
is also not useful in individuals with a history of 
extensive ileocolonic resections. Third, the ELISA 
method used to assess microparticle activity is not 
the gold standard for that measurement. Final‑
ly, the study groups differed regarding the type 
of medications taken. We analyzed their associ‑
ations with the analyzed parameters. However, 
a relatively small number of patients in the sub‑
groups may result in lack of significance when 
calculating differences.
On the other hand, the strengths of this study 
included strict exclusion criteria, ruling out any 
influence of non ‑IBD diseases.
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